Novelion Therapeutics (NVLN) Stock Price, News & Analysis

Company Overview

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.68 to $0.70
• 52-Week Range: N/A
• Volume: 26,947 shs
• Average Volume: 190,529 shs
• Market Capitalization: $13.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NVLN Stock Analysis - Frequently Asked Questions

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc. (NASDAQ:NVLN) posted its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.13. The biotechnology company had revenue of $40.71 million for the quarter, compared to analyst estimates of $40.90 million.

What other stocks do shareholders of Novelion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novelion Therapeutics investors own include Aralez Pharmaceuticals (ARLZ), Applied Genetic Technologies (AGTC), Biocept (BIOC), Bristol-Myers Squibb (BMY), Karyopharm Therapeutics (KPTI), Actinium Pharmaceuticals (ATNM) and Amicus Therapeutics (FOLD).

Company Calendar

• Last Earnings: 3/14/2019
• Today: 1/29/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NVLN
• CUSIP: N/A
• CIK: 827809
• Web: www.novelion.com
• Phone: 617-500-7867
• Fax: N/A
• Employees: 109
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-108,330,000.00
• Net Margins: -79.43%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -26.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.24
• Quick Ratio: 0.21

Sales & Book Value

• Annual Sales: $130.43 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.69) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 19,619,000
• Free Float: N/A
• Market Cap: $13.77 million
• Optionable: Optionable
• Beta: 2.12